Physician profile
Carlos Zem
NPI 1437237914
$1,311.92
in general payments reported to CMS, 2019-2025
19 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $19.24 · 2021: $106 · 2022: $118 · 2023: $293 · 2024: $216 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $733 · Education: $39.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $733.45 |
| Education | $39.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $269.67 | 2019-2025 | Rayaldee |
| Novo Nordisk INC | $163.50 | 2021-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $134.42 | 2024 | |
| Medtronic, INC. | $118.18 | 2023 | Ellipsys Vascular Access System |
| Fresenius USA Marketing, INC. | $116.26 | 2019-2022 | |
| Akebia Therapeutics INC | $99.26 | 2019 | |
| Glaxosmithkline, LLC. | $98.67 | 2022-2025 | Jesduvroq, Benlysta |
| Lilly USA, LLC | $70.18 | 2024-2025 | Jardiance |
| Horizon Therapeutics Plc | $58.57 | 2019-2021 | |
| Nxstage Medical, INC. | $26.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $26.50 | 2024 | |
| Scpharmaceuticals INC. | $20.10 | 2025 | |
| Daiichi Sankyo INC. | $19.24 | 2020 | |
| Ardelyx, INC. | $18.89 | 2024 | Ibsrela |
| Ultragenyx Pharmaceutical INC. | $16.24 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $16.02 | 2022 | |
| Xeris Pharmaceuticals, INC. | $13.79 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.22 | 2019 | |
| Shire North American Group INC | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Zem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.